Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT00433511 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer

StatusActive, Not Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

The 50 most recent of 1151 record versions are listed below. See every version on ClinicalTrials.gov ↗

  1. Study sites revised (842)
  2. Study sites revised (842)v1150 See this version in full on ClinicalTrials.gov ↗
  3. Re-verified, no change to tracked fieldsv1149
  4. Study sites: 843 to 842v1148
  5. Study sites revised (843)v1147 See this version in full on ClinicalTrials.gov ↗
  6. Completion pushed from Feb 22, 2026 to Feb 20, 2027 Study sites revised (843)v1146 Show 1 more changeShow less
    • Study sites revised (843)

    See this version in full on ClinicalTrials.gov ↗

  7. Study sites revised (843)v1145 See this version in full on ClinicalTrials.gov ↗
  8. Study sites revised (843)v1144 See this version in full on ClinicalTrials.gov ↗
  9. Study sites revised (843)v1143 See this version in full on ClinicalTrials.gov ↗
  10. Study sites: 844 to 843v1142
  11. Study sites revised (844)v1141 See this version in full on ClinicalTrials.gov ↗
  12. Re-verified, no change to tracked fieldsv1140
  13. Study sites revised (844)v1139 See this version in full on ClinicalTrials.gov ↗
  14. Study sites revised (844)v1138 See this version in full on ClinicalTrials.gov ↗
  15. Study sites revised (844)v1137 See this version in full on ClinicalTrials.gov ↗
  16. Study sites revised (844)v1136 See this version in full on ClinicalTrials.gov ↗
  17. Completion date: Feb 22, 2025 to Feb 22, 2026 Study sites revised (844)v1135 Show 1 more changeShow less
    • Study sites revised (844)

    See this version in full on ClinicalTrials.gov ↗

  18. Study sites revised (844)v1134 See this version in full on ClinicalTrials.gov ↗
  19. Re-verified, no change to tracked fieldsv1133
  20. Study sites revised (844)v1132 See this version in full on ClinicalTrials.gov ↗
  21. Study sites revised (844)v1131 See this version in full on ClinicalTrials.gov ↗
  22. Study sites revised (844)v1130 See this version in full on ClinicalTrials.gov ↗
  23. Study sites revised (844)v1129 See this version in full on ClinicalTrials.gov ↗
  24. Study sites revised (844)v1128 See this version in full on ClinicalTrials.gov ↗
  25. Study sites revised (844)v1127 See this version in full on ClinicalTrials.gov ↗
  26. Study sites: 849 to 844v1126
  27. Study sites revised (849)v1125 See this version in full on ClinicalTrials.gov ↗
  28. Study sites revised (849)v1124 See this version in full on ClinicalTrials.gov ↗
  29. Study sites revised (849)v1123 See this version in full on ClinicalTrials.gov ↗
  30. Re-verified, no change to tracked fieldsv1122
  31. Study sites revised (849)v1121 See this version in full on ClinicalTrials.gov ↗
  32. Study sites revised (849)v1120 See this version in full on ClinicalTrials.gov ↗
  33. Study sites revised (849)v1119 See this version in full on ClinicalTrials.gov ↗
  34. Study sites revised (849)v1118 See this version in full on ClinicalTrials.gov ↗
  35. Study sites revised (849)v1117 See this version in full on ClinicalTrials.gov ↗
  36. Study sites revised (849)v1116 See this version in full on ClinicalTrials.gov ↗
  37. Study sites revised (849)v1115 See this version in full on ClinicalTrials.gov ↗
  38. Study sites revised (849)v1114 See this version in full on ClinicalTrials.gov ↗
  39. Completion date: Feb 22, 2025v1113
  40. Study sites revised (849)v1112 See this version in full on ClinicalTrials.gov ↗
  41. Study sites revised (849)v1111 See this version in full on ClinicalTrials.gov ↗
  42. Re-verified, no change to tracked fieldsv1110
  43. Study sites revised (849)v1109 See this version in full on ClinicalTrials.gov ↗
  44. Study sites revised (849)v1108 See this version in full on ClinicalTrials.gov ↗
  45. Study sites revised (849)v1107 See this version in full on ClinicalTrials.gov ↗
  46. Re-verified, no change to tracked fieldsv1106
  47. Study sites revised (849)v1105 See this version in full on ClinicalTrials.gov ↗
  48. Study sites revised (849)v1104 See this version in full on ClinicalTrials.gov ↗
  49. Study sites revised (849)v1103 See this version in full on ClinicalTrials.gov ↗
  50. Re-verified, no change to tracked fieldsv1102
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This randomized phase III trial studies doxorubicin hydrochloride, cyclophosphamide, and paclitaxel to see how well they work with or without bevacizumab in treating patients with cancer that has spread to the lymph nodes (lymph node-positive) or cancer that has not spread to the lymph nodes but is at high risk for returning (high-risk, lymph node-negative breast cancer). Drugs used in chemotherapy, such as doxorubicin hydrochloride, cyclophosphamide, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as bevacizumab, may interfere with the ability of tumor cells to grow and spread. Bevacizumab may also stop the growth of breast cancer by blocking blood flow to the tumor. Giving chemotherapy after surgery may kill any tumor cells that remain after surgery and help prevent the tumor from returning. It is not yet known whether doxorubicin hydrochloride, cyclophosphamide, and paclitaxel are more effective with or without bevacizumab.
Trial Details
NCT Number NCT00433511
Lead Sponsor National Cancer Institute (NCI)
Collaborators: Cancer and Leukemia Group B, Eastern Cooperative Oncology Group, North Central Cancer Treatment Group
Conditions Breast Adenocarcinoma
Enrollment 4,994 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov